<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132846</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00024136</org_study_id>
    <secondary_id>U01HL084904</secondary_id>
    <secondary_id>Pro00029908</secondary_id>
    <secondary_id>Pro00023578</secondary_id>
    <nct_id>NCT01132846</nct_id>
  </id_info>
  <brief_title>Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study</brief_title>
  <acronym>ROSE/RED ROSE</acronym>
  <official_title>Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network ROSE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the benefits and safety of intravenous
      administration of low dose nesiritide or low dose dopamine in patients with congestive heart
      failure and kidney dysfunction. There is a substudy in a subset of subjects that is being
      used to determine whether the Provocative Dyspnea Severity Score (pDSS) is a more sensitive
      index of variability in clinical status than the dyspnea VAS assessed without standardization
      of conditions at assessments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute heart failure (AHF) is the most common cause of hospital admission in patients over age
      65, accounting for 1,000,000 admissions, over 6 million hospital days, and $12 billion in
      costs annually. The prognosis of patients admitted with AHF is dismal, with a 20-30%
      readmission rate and a 20-30% mortality rate within six months after admission. Recent
      studies have established the prognostic importance of renal function in patients with heart
      failure. In patients who are hospitalized with decompensated congestive heart failure,
      worsening renal function is also associated with worse outcome, Various studies have
      estimated that 25-30% of patients hospitalized for decompensated CHF have worsening of renal
      function leading to prolonged hospitalization, increased morbidity and mortality. Although
      there are no FDA approved renal adjuvant therapies for AHF, several novel adjuvant therapies
      for use in AHF are being investigated in randomized clinical trials. Additionally, there are
      currently available strategies, with the potential for improving renal function in AHF such
      as low dose dopamine and low dose nesiritide. However, these strategies have not been
      investigated.

      Participation in this study will last 6 months. All potential participants will undergo
      initial screening, which wil include a medical history, physical exam, blood draws,
      measurements of fluid intake and output, and questionnaires. The same evaluations and
      procedures will be repeated at various points during the study. Eligible participants will be
      randomly assigned to receive low dose nesiritide or placebo with optimal diuretic dosing or
      low dose dopamine or placebo with optimal diuretic dosing.

      Follow-up assessments will occur at Baseline, 24 hours, 48 hours, 72 hours, day 7 or
      discharge, day 60 and 6 months. Follow-up assessments will include medical history, physical
      exam, blood draws, measurements of fluid intake and output, questionnaires and questions
      about medications and changes in health.

      The RED ROSE substudy involves a subset of ROSE patients in looking at the dyspnea
      assessment. The dyspnea visual analog scale (dyspnea VAS) has been suggested to be superior
      to other ordinal (Likert) scales in assessment of dyspnea in acute heart failure syndromes
      (AHFS)1. However, there is no standardization of conditions (oxygen supplementation,
      position, activity) at the time of VAS assessment and thus, it may not optimally reflect the
      variability in dyspnea severity in AHFS patients. This insensitivity to variability at
      baseline and subsequent assessment may limit the ability to reflect variation in response
      over time and with alternate treatment strategies. A standardized and sequentially
      provocative assessment of dyspnea (provocative dyspnea severity score, pDSS) may better
      reflect variation in dyspnea severity and variation in response over time and with alternate
      treatment strategies. Substudy subjects will be asked to complete a provocative dyspnea
      assessment at baseline, 24, 48 and 72 hours. The subjects will be asked to complete a 6
      minute walk assessment at the 72 hour visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cystatin C</measure>
    <time_frame>Randomization to 72 hours</time_frame>
    <description>The primary Safety endpoint is change in serum cystatin C from randomization to 72 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Dyspnea Assessment (RED-ROSE Substudy)</measure>
    <time_frame>Baseline to 72 hours</time_frame>
    <description>To determine whether the pDSS is a more sensitive index of variability in dyspnea status than the dyspnea VAS assessed without standardization of conditions at assessment as assessed by change in Dyspnea VAS.
Dyspnea VAS range -100 to + 100 Larger number is better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decongestive Changes- RED-ROSE</measure>
    <time_frame>Baseline to 72 hours</time_frame>
    <description>To determine whether changes in pDSS or dyspnea VAS are related to the response to decongestive therapy as evidenced by fluid volume loss
Fluid volume loss is defined as cumulative urinary output minus fluid intake during the first 72 hours post randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Urinary Volume</measure>
    <time_frame>Randomization to 72 hours</time_frame>
    <description>The primary efficacy endpoint is cumulative urinary volume (UV; +/- indwelling urinary catheter) at 72 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>randomization to 72 hours</time_frame>
    <description>Change in weight from randomization to 72 hours. Secondary Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Reported Symptom Changes-RED-ROSE</measure>
    <time_frame>Change from Baseline to 72 hours</time_frame>
    <description>To determine whether changes in worst reported symptom (WRS) (dyspnea, body swelling or fatigue) VAS (WRS-VAS) are related to the response to decongestive therapy as assessed by change in WRS VAS.
WRS range -100 to + 100 Higher number is better (improved)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Stability- RED-ROSE</measure>
    <time_frame>Baseline to 60 days</time_frame>
    <description>Change in clinical stability as assessed by 60 day death, re-hospitalization or unscheduled outpatient visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>randomization to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea Visual Analog Scale Area Under the Curve</measure>
    <time_frame>randomization to 72 hours</time_frame>
    <description>Range 0 to 7200 Higher is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Failure Status</measure>
    <time_frame>randomization to 72 hours</time_frame>
    <description>Persistent or worsening heart failure defined as need for rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Treatment Response</measure>
    <time_frame>randomization to 72 hours</time_frame>
    <description>Treatment failure including any of the following:
development of cardio-renal syndrome
worsening/persistent heart failure
significant hypotension requiring discontinuation of study drug
significant tachycardia requiring discontinuation of study drug death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Urinary Sodium Excretion</measure>
    <time_frame>Randomization to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Urea Nitrogen (BUN)/ Serum Cystatin C Ratio</measure>
    <time_frame>Randomization to 72 hours</time_frame>
    <description>BUN measured in mg/dL Cystatin C measured in mg/L
No units were used in calculated the ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Cardio-renal Syndrome</measure>
    <time_frame>Randomization to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Visual Analog Scale Area Under the Curve</measure>
    <time_frame>Randomization to 72 hours</time_frame>
    <description>Range 0 to 7200 Higher is better/improved</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Low dose Dopamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Nesiritide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nesiritide</intervention_name>
    <description>Active Comparator: Low Dose Nesiritide
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
    <arm_group_label>Low Dose Nesiritide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dopamine</intervention_name>
    <description>Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
    <arm_group_label>Low dose Dopamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of heart failure as defined by the presence of at least 1 symptom
             (dyspnea, orthopnea, or edema) AND 1 sign (rales on auscultation, peripheral edema,
             ascites, pulmonary vascular congestion on chest radiography)

          -  Prior clinical diagnosis of heart failure Must be identified within 24 hours of
             hospital admission (24 hour clock begins when the admission orders are placed)

          -  Estimated GFR of &gt; 15 but &lt; 60 mL/min/1.73m2 determined by the MDRD equation

          -  Male or female patient ≥18 years old

          -  Willingness to provide informed consent

          -  Ability to have a PICC or central line placed (if needed) within 12 hours of
             randomization and study drug infusion started

          -  Anticipated hospitalization of at least 72 hours

        Exclusion Criteria:

          -  Received IV vasoactive treatment or ultra-filtration therapy for heart failure since
             initial presentation

          -  Anticipated need for IV vasoactive treatment or ultra-filtration for heart failure
             during this hospitalization

          -  Systolic BP &lt;90 mmHg

          -  Hemoglobin (Hgb) &lt; 9 g/dl

          -  Renal replacement therapy

          -  History of renal artery stenosis &gt; 50%

          -  Hemodynamically significant arrhythmias including ventricular tachycardia or
             defibrillator shock within 4 weeks

          -  Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG)
             ST-segment depression or prominent T-wave inversion and/or positive biomarkers of
             necrosis (e.g., troponin) in the absence of ST-segment elevation and in an appropriate
             clinical setting (chest discomfort or anginal equivalent)

          -  Active myocarditis

          -  Hypertrophic obstructive cardiomyopathy

          -  Greater than moderate stenotic valvular disease

          -  Restrictive or constrictive cardiomyopathy

          -  Complex congenital heart disease

          -  Constrictive pericarditis

          -  Non-cardiac pulmonary edema

          -  Clinical evidence of digoxin toxicity

          -  Need for mechanical hemodynamic support

          -  Sepsis

          -  Terminal illness (other than HF) with expected survival of less than 1 year

          -  Previous adverse reaction to the study drugs

          -  Use of IV iodinated radiocontrast material in last 72 hours or planned during
             hospitalization

          -  Enrollment or planned enrollment in another randomized clinical trial during this
             hospitalization

          -  Inability to comply with planned study procedures

          -  Pregnancy or nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry L Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Braunwald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Heart Failure Network</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Murry</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont- Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T- 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18;310(23):2533-43. doi: 10.1001/jama.2013.282190.</citation>
    <PMID>24247300</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <results_first_submitted>July 7, 2014</results_first_submitted>
  <results_first_submitted_qc>August 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2014</results_first_posted>
  <last_update_submitted>August 20, 2014</last_update_submitted>
  <last_update_submitted_qc>August 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Dopamine</title>
          <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
        </group>
        <group group_id="P3">
          <title>Low Dose Nesiritide</title>
          <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Dopamine</title>
          <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
        </group>
        <group group_id="B3">
          <title>Low Dose Nesiritide</title>
          <description>Drug: Nesiritide Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="119"/>
            <count group_id="B4" value="360"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" spread="11.1"/>
                    <measurement group_id="B2" value="69.3" spread="12.6"/>
                    <measurement group_id="B3" value="68.3" spread="13.0"/>
                    <measurement group_id="B4" value="69.6" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cystatin C</title>
        <description>The primary Safety endpoint is change in serum cystatin C from randomization to 72 hours.</description>
        <time_frame>Randomization to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystatin C</title>
          <description>The primary Safety endpoint is change in serum cystatin C from randomization to 72 hours.</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".12" spread=".32"/>
                    <measurement group_id="O2" value=".11" spread=".27"/>
                    <measurement group_id="O3" value=".07" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Dyspnea Assessment (RED-ROSE Substudy)</title>
        <description>To determine whether the pDSS is a more sensitive index of variability in dyspnea status than the dyspnea VAS assessed without standardization of conditions at assessment as assessed by change in Dyspnea VAS.
Dyspnea VAS range -100 to + 100 Larger number is better</description>
        <time_frame>Baseline to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dyspnea Assessment (RED-ROSE Substudy)</title>
          <description>To determine whether the pDSS is a more sensitive index of variability in dyspnea status than the dyspnea VAS assessed without standardization of conditions at assessment as assessed by change in Dyspnea VAS.
Dyspnea VAS range -100 to + 100 Larger number is better</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="30.7"/>
                    <measurement group_id="O2" value="16.2" spread="22.3"/>
                    <measurement group_id="O3" value="16.8" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Decongestive Changes- RED-ROSE</title>
        <description>To determine whether changes in pDSS or dyspnea VAS are related to the response to decongestive therapy as evidenced by fluid volume loss
Fluid volume loss is defined as cumulative urinary output minus fluid intake during the first 72 hours post randomization.</description>
        <time_frame>Baseline to 72 hours</time_frame>
        <population>RED-ROSE is a substudy of the overall ROSE study. Only consented and enrolled RED-ROSE subjects participated.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Decongestive Changes- RED-ROSE</title>
          <description>To determine whether changes in pDSS or dyspnea VAS are related to the response to decongestive therapy as evidenced by fluid volume loss
Fluid volume loss is defined as cumulative urinary output minus fluid intake during the first 72 hours post randomization.</description>
          <population>RED-ROSE is a substudy of the overall ROSE study. Only consented and enrolled RED-ROSE subjects participated.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4526.0" spread="3191.9"/>
                    <measurement group_id="O2" value="4659.9" spread="2862.5"/>
                    <measurement group_id="O3" value="5177.2" spread="2830.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Urinary Volume</title>
        <description>The primary efficacy endpoint is cumulative urinary volume (UV; +/- indwelling urinary catheter) at 72 hours</description>
        <time_frame>Randomization to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Urinary Volume</title>
          <description>The primary efficacy endpoint is cumulative urinary volume (UV; +/- indwelling urinary catheter) at 72 hours</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8524" spread="3418"/>
                    <measurement group_id="O2" value="8296" spread="2973"/>
                    <measurement group_id="O3" value="8574" spread="3115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <description>Change in weight from randomization to 72 hours. Secondary Endpoint</description>
        <time_frame>randomization to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>Change in weight from randomization to 72 hours. Secondary Endpoint</description>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.40" spread="7.94"/>
                    <measurement group_id="O2" value="-7.73" spread="7.04"/>
                    <measurement group_id="O3" value="-7.15" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Reported Symptom Changes-RED-ROSE</title>
        <description>To determine whether changes in worst reported symptom (WRS) (dyspnea, body swelling or fatigue) VAS (WRS-VAS) are related to the response to decongestive therapy as assessed by change in WRS VAS.
WRS range -100 to + 100 Higher number is better (improved)</description>
        <time_frame>Change from Baseline to 72 hours</time_frame>
        <population>RED-ROSE was a substudy of the main ROSE study. Only subjects consented and enrolled in RED-ROSE were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Reported Symptom Changes-RED-ROSE</title>
          <description>To determine whether changes in worst reported symptom (WRS) (dyspnea, body swelling or fatigue) VAS (WRS-VAS) are related to the response to decongestive therapy as assessed by change in WRS VAS.
WRS range -100 to + 100 Higher number is better (improved)</description>
          <population>RED-ROSE was a substudy of the main ROSE study. Only subjects consented and enrolled in RED-ROSE were included in this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="29.6"/>
                    <measurement group_id="O2" value="19.6" spread="22.7"/>
                    <measurement group_id="O3" value="25.6" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Stability- RED-ROSE</title>
        <description>Change in clinical stability as assessed by 60 day death, re-hospitalization or unscheduled outpatient visit</description>
        <time_frame>Baseline to 60 days</time_frame>
        <population>RED-ROSE was a substudy of the main ROSE trial. Only subjects consented and enrolled in RED-ROSE were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Stability- RED-ROSE</title>
          <description>Change in clinical stability as assessed by 60 day death, re-hospitalization or unscheduled outpatient visit</description>
          <population>RED-ROSE was a substudy of the main ROSE trial. Only subjects consented and enrolled in RED-ROSE were included in this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <time_frame>randomization to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.44"/>
                    <measurement group_id="O2" value="0.02" spread="0.33"/>
                    <measurement group_id="O3" value="0.02" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea Visual Analog Scale Area Under the Curve</title>
        <description>Range 0 to 7200 Higher is better</description>
        <time_frame>randomization to 72 hours</time_frame>
        <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea Visual Analog Scale Area Under the Curve</title>
          <description>Range 0 to 7200 Higher is better</description>
          <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
          <units>units on a scale * hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4935.8" spread="1472.1"/>
                    <measurement group_id="O2" value="4997.6" spread="1479.9"/>
                    <measurement group_id="O3" value="4831.4" spread="1294.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Failure Status</title>
        <description>Persistent or worsening heart failure defined as need for rescue therapy.</description>
        <time_frame>randomization to 72 hours</time_frame>
        <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Failure Status</title>
          <description>Persistent or worsening heart failure defined as need for rescue therapy.</description>
          <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Treatment Response</title>
        <description>Treatment failure including any of the following:
development of cardio-renal syndrome
worsening/persistent heart failure
significant hypotension requiring discontinuation of study drug
significant tachycardia requiring discontinuation of study drug death</description>
        <time_frame>randomization to 72 hours</time_frame>
        <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Treatment Response</title>
          <description>Treatment failure including any of the following:
development of cardio-renal syndrome
worsening/persistent heart failure
significant hypotension requiring discontinuation of study drug
significant tachycardia requiring discontinuation of study drug death</description>
          <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Urinary Sodium Excretion</title>
        <time_frame>Randomization to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Urinary Sodium Excretion</title>
          <units>mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527.0" spread="299.0"/>
                    <measurement group_id="O2" value="539.8" spread="302.7"/>
                    <measurement group_id="O3" value="515.2" spread="261.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Urea Nitrogen (BUN)/ Serum Cystatin C Ratio</title>
        <description>BUN measured in mg/dL Cystatin C measured in mg/L
No units were used in calculated the ratio</description>
        <time_frame>Randomization to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Urea Nitrogen (BUN)/ Serum Cystatin C Ratio</title>
          <description>BUN measured in mg/dL Cystatin C measured in mg/L
No units were used in calculated the ratio</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.34" spread="25.33"/>
                    <measurement group_id="O2" value="0.23" spread="5.16"/>
                    <measurement group_id="O3" value="0.74" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Cardio-renal Syndrome</title>
        <time_frame>Randomization to 72 hours</time_frame>
        <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Cardio-renal Syndrome</title>
          <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Visual Analog Scale Area Under the Curve</title>
        <description>Range 0 to 7200 Higher is better/improved</description>
        <time_frame>Randomization to 72 hours</time_frame>
        <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Dopamine</title>
            <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Nesiritide</title>
            <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Visual Analog Scale Area Under the Curve</title>
          <description>Range 0 to 7200 Higher is better/improved</description>
          <population>Based upon data completeness, sample size for this endpoint does not match the overall ROSE population.</population>
          <units>units on a scale * hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4553.4" spread="1324.9"/>
                    <measurement group_id="O2" value="4703.6" spread="1403.4"/>
                    <measurement group_id="O3" value="4498.3" spread="1301.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Dopamine</title>
          <description>Drug: Dopamine
Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study
Dopamine: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Drug: Placebo
Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
Placebo: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.</description>
        </group>
        <group group_id="E3">
          <title>Low Dose Nesiritide</title>
          <description>Drug: Nesiritide
Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block, Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Paroxysmal Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroesophogeal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion Site Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Procedural Complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation Drug Level Above Therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin Anstrom</name_or_title>
      <organization>Duke University</organization>
      <phone>919-668-8902</phone>
      <email>kevin.anstrom@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

